Abstract
Due to the achievements of world scientific thought, clinical diagnostic laboratories and diagnostic centers have been given the opportunity to analyze a huge number of biochemical markers of various nature, and their arsenal is replenished from year to year. This article discusses a complex of valid biomarkers, combined for the purpose of biomedical preclinical diagnosis and prevention of cardiovascular diseases. As a justification for the choice of these biochemical markers, we gave trigger processes that underlie the development of cardiovascular pathology, with which selected biochemical markers are associated. The diagnostic complex is based on the “necessity and sufficiency” principle, taking into account financial feasibility, and the ability to measure selected markers in a wide network of clinical diagnostic centers or laboratories. The review is intended to help clinicians with a view to a more detailed understanding of the initial, preclinical stages of cardiovascular diseases, as the most common cause of mortality in Russia, as well as for a wide audience studying or specializing in cardiology.
Highlights
Due to the achievements of world scientific thought, clinical diagnostic laboratories and diagnostic centers have been given the opportunity to analyze a huge number of biochemical markers of various nature, and their arsenal is replenished from year to year
This article discusses a complex of valid biomarkers, combined for the purpose of biomedical preclinical diagnosis and prevention of cardiovascular diseases
As a justification for the choice of these biochemical markers, we gave trigger processes that underlie the development of cardiovascular pathology, with which selected biochemical markers are associated
Summary
Чтобы определить комплекс биохимических маркеров для оценки риска развития сердечнососудистых заболеваний (ССЗ), необходимо выделить начальные, триггерные состояния, лежащие в основе развития сердечно-сосудистой патологии. Повышенный индекс массы тела и ИР — практически гаранты хронического воспаления, что подтверждается прочной взаимосвязью между уровнем CРБ, абдоминальным ожирением и ИР [10], где на репрезентативной выборке жителей США — 8570 человек >20 лет, у пациентов с МС, который диагностировали по критериям NCEP-ATP III (National Cholesterol Education Program’s Adult Treatment Panel III), как правило, обнаруживали более высокий уровень маркеров воспаления — СРБ, фибриногена и лейкоцитов [10].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
